The Food and Drug Administration issued a nationwide alert on November 1, 2024 that patients and health‑care providers must stop using injectable drugs compounded by Fullerton Wellness LLC. The warning targets semaglu…

Fullerton Wellness, a California‑based compounding facility, distributed the injections to medical offices and clinics across the United States.[^1][^2][^3][^4][^5][^6] The FDA’s notice cites a patient complaint on Au…

The agency’s advisory instructs clinicians to quarantine any Fullerton‑sourced supplies, verify inventory, and refrain from administering the drugs.[^1][^2][^3][^4][^5] Patients who have received the compounded inject…

Fullerton Wellness’s practices illustrate a regulatory blind spot that has persisted for years. Compounding pharmacies that are not registered with the FDA as outsourcing facilities fall under the primary jurisdiction…